Development of ABL1 tyrosine kinase inhibitors (TKI) in the past decade provided the proof of concept that targeted therapies are an attractive strategy in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.